Lannett Company Inc (NYSE:LCI), a provider of generic pharmaceutical products, said on Tuesday that it plans to issue USD75m aggregate principal amount of convertible senior notes due 2026 in a private placement subject to market conditions and other factors.
The company added that it will provide the initial purchaser of the notes with a 30-day option to purchase up to an additional USD11.25m aggregate principal amount of the notes.
According to the company, the notes are expected to pay interest semiannually. Conversion of the Notes will be settled in shares of its common stock. The notes will mature on 1 October 2026, unless earlier converted, redeemed or repurchased in accordance with their terms.
Net proceeds from the offering may be used by the company to pay the cost of the capped call transaction, to repay a portion of its existing Term Loan A under its existing senior credit facility, to enter into an additional capped call transaction with the capped call counterparty as well as to repay a portion of its existing Term Loan A under its existing senior credit facility.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic